Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

NCT05668767 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: Surufatinib Durvalizumab EP/EC

Sponsor

Beijing Chest Hospital